ArticleBMC musculoskeletal disorders2026
Ultrasound-guided platelet-rich plasma myofascial injection for chronic low back pain: a retrospective study.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveRetrospective cohort study to evaluate the efficacy and safety of ultrasound-guided myofascial platelet-rich plasma (PRP) injection for myofascial pain syndrome (MPS)-induced chronic low back pain.
methodsFifty-eight patients treated between May and December 2024 received a single ultrasound-guided PRP injection (n = 32) or two weekly normal saline injections (n = 26), and both groups underwent myofascial hydrodissection targeting trigger points in the longissimus lumborum. Pain intensity was assessed via Visual Analog Scale (VAS), functional disability by the Oswestry Disability Index (ODI). Surface electromyography (sEMG) measured neuromuscular activity through root mean square (RMS) and median frequency (MF). Statistical analyses used SPSS v.27.
resultsBoth groups showed significant VAS reduction at 12 weeks (p < 0.001), with greater improvement in the PRP group (r = 0.501). PRP also yielded significant ODI improvement (r = 0.611) exceeding the minimum clinically important difference. RMS values decreased markedly in the PRP group (p = 0.001) and modestly in the NS group (p = 0.006). MF demonstrated a transient decline at week 4 (p = 0.014). No adverse events occurred.
conclusionsUltrasound-guided myofascial PRP injection effectively reduces pain, enhances function, and modulates MTrPs activity in MPS at short-term follow-up, with good safety. These results support further randomized trials to validate the rehabilitative benefits of PRP for chronic low back pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.